Watts Ryan J.'s Form 4 filing
Denali Therapeutics Inc. (DNLI) · filed Apr 24, 2023
- Accession no.
- 0001714899-23-000066
- Filed
- Apr 24, 2023
- Trade date
- Apr 20-21, 2023
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market sales total $628.7K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Watts Ryan J.CIK 0001724310 | Director, Officer (President and CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 20, 2023 | Common Stock | MOption exerciseAcquired | +200 | $0.68 | +$136 | 2,240,113 | Indirect | |
| Apr 20, 2023 | Common Stock | SSaleDisposed | −200 | $25.00 | −$5,000 | 2,239,913 | Indirect | |
| Apr 21, 2023 | Common Stock | MOption exerciseAcquired | +24,800 | $0.68 | +$16,864 | 2,264,713 | Indirect | |
| Apr 21, 2023 | Common Stock | SSaleDisposed | −24,800 | $25.15F3 | −$623,720 | 2,239,913 | Indirect |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 20, 2023 | Common Stock | MOption exerciseDisposed | −200 | $0.00 | $0 | 1,195,417 | Direct | |
| Apr 21, 2023 | Common Stock | MOption exerciseDisposed | −24,800 | $0.00 | $0 | 1,170,617 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F3
The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $25.00 to $25.36 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.